Maarten Cozijnsen

104                            Figure 2. Adalimumab failure over time Cumulative longitudinal adalimumab failure: Within 12 months 24% of the patients failed adalimumab therapy, rising to 42% within 24 months.                                       Figure 3. Comparing the risk of adalimumab failure in non-responders vs. patients who lost response to infliximab Kaplan-Meier analysis displaying adalimumab failure over time separately for patients that had not responded to or had lost response to infliximab. Within 4.7 months, two out of three non-responders failed adalimumab therapy, for the other patient no more follow-up was available. Patients with non- response to infliximab had higher risk for adalimumab failure than patients who had lost response (HR 18.8, CI 1.1-303.6).